Digitalis Promotes Ventricular Arrhythmias in Flecainide- and Ranolazine-Pretreated Hearts
- 54 Downloads
A post hoc analysis of the PALLAS trial suggested life-threatening interactions of digitalis and dronedarone. Thus, there is concern about an interplay between digitalis and other drugs that influence cardiac electrophysiology. We therefore investigated the interaction between digitalis and flecainide or ranolazine. Twenty-five rabbit hearts were Langendorff-perfused and treated with flecainide (2 µM, 12 hearts) or ranolazine (10 µM, 13 hearts). Infusion of flecainide prolonged mean action potential duration [APD90, from 153 ms (interquartile range (IQR): 29.7 ms) to 159 ms (IQR: 24.9 ms, p = 0.04)] and effective refractory period [ERP, 170 ms (IQR: 40 ms) vs. 200 ms (IQR: 32.5 ms, p < 0.01)]. Administration of ranolazine prolonged APD90 [144 ms (IQR: 34.3 ms)) vs. 157 ms (IQR: 31.2 ms, p < 0.01)] and ERP [180 ms (IQR: 40 ms) vs. 200 ms (IQR: 30 ms, p < 0.01)]. Additional infusion of the digitalis glycoside ouabain (0.2 µM) abbreviated APD90 and ERP in both groups (flecainide: APD90: to 128 ms (IQR: 19 ms), ERP: to 170 ms (IQR: 20 ms), p < 0.01 each; ranolazine: APD90: to 141 ms (IQR: 40 ms), ERP: to 160 ms (IQR: 30 ms), p < 0.01 each). Ventricular vulnerability was assessed by a pacing protocol employing premature extra stimuli and burst stimulation. No proarrhythmic effect was observed with flecainide (1 vs. 3 episodes at baseline) or ranolazine (3 vs. 11 episodes at baseline). However, further infusion of ouabain had a proarrhythmic effect for both drugs (flecainide: 15 episodes, p = 0.04; ranolazine: 21 episodes, p = 0.09). Concomitant treatment of the sodium channel blockers flecainide or ranolazine with digitalis seems to be proarrhythmic. Abbreviation of repolarization and refractoriness that can facilitate re-entry was found as underlying mechanism.
KeywordsDigitalis Flecainide Ranolazine Ventricular arrhythmias Sudden cardiac death
This study was supported by the Hans-and-Gertie Fischer Foundation and by the German Cardiac Society (to G.F.).
Compliance with Ethical Standards
Conflict of interest
All other authors declare to have no conflict of interest.
Ethical Approval and Statement
All applicable international, national and institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.
- 4.Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., et al. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129–2200.CrossRefPubMedGoogle Scholar
- 5.Eisen, A., Ruff, C. T., Braunwald, E., Hamershock, R. A., Lewis, B. S., Hassager, C., et al. (2017). Digoxin use and subsequent clinical outcomes in patients with atrial fibrillation with or without heart failure in the ENGAGE AF-TIMI 48 trial. Journal of the American Heart Association, 6(7), e006035.CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Washam, J. B., Stevens, S. R., Lokhnygina, Y., Halperin, J. L., Breithardt, G., Singer, D. E., et al. (2015). Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: A retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). The Lancet, 385(9985), 2363–2370.CrossRefGoogle Scholar
- 10.Hohnloser, S. H., Halperin, J. L., Camm, A. J., Gao, P., Radzik, D., & Connolly, S. J. Interaction between digoxin and dronedarone in the PALLAS trial. Circulation: Arrhythmia and Electrophysiology. 2014:7(6), 1019.Google Scholar
- 16.Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., et al. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34(38), 2949–3003.CrossRefPubMedGoogle Scholar
- 17.Reiffel, J. A., Camm, A. J., Belardinelli, L., Zeng, D., Karwatowska-Prokopczuk, E., Olmsted, A., et al. The HARMONY trial: Combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism. Circulation: Arrhythmia and Electrophysiology. 2015:CIRCEP. 115.002856..Google Scholar
- 19.Frommeyer, G., Milberg, P., Uphaus, T., Kaiser, D., Kaese, S., Breithardt, G., et al. (2013). Antiarrhythmic effect of ranolazine in combination with class III drugs in an experimental whole-heart model of atrial fibrillation. Cardiovascular Therapeutics, 31(6), e63–e71. https://doi.org/10.1111/1755-5922.12035.CrossRefPubMedGoogle Scholar
- 20.Frommeyer, G., Ellermann, C., Dechering, D. G., Kochhäuser, S., Bögeholz, N., Güner, F., et al. (2016). Ranolazine and vernakalant prevent ventricular arrhythmias in an experimental whole-heart model of short QT syndrome. Journal of Cardiovascular Electrophysiology, 27(10), 1214–1219.CrossRefPubMedGoogle Scholar
- 22.Frommeyer, G., Sterneberg, M., Dechering, D. G., Kaese, S., Bögeholz, N., Pott, C., et al. (2017). Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: First experimental insights into a novel antiarrhythmic agent. Cardiovascular Therapeutics, 35(2), e12244.CrossRefGoogle Scholar